PathAI Announces EMA Qualification for AIM-MASH AI Assist, a Groundbreaking AI Tool for MASH Clinical Trials
PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for ...
Morningstar12d
PathAI Announces EMA Qualification for AIM-MASH AI Assist, a Groundbreaking AI Tool for MASH Clinical Trials
The EMA CHMP has determined that the proposed Artificial Intelligence-Based Measurement of Non-alcoholic Steatohepatitis Histology (AIM-MASH) tool can be used in metabolic dysfunction associated ...
Medscape5d
EMA Approves AI Tool for MASH Clinical Trials
The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...
heise online10d
EU Medicines Agency assesses first AI diagnosis as "scientifically valid"
The tool, called AIM-NASH (Artificial Intelligence-Based Measurement of Non-alcoholic Steatohepatitis Histology) from Boston-based Path AI, supports pathologists in analyzing liver biopsy scans to ...
Pharmabiz10d
EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples
EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...
Science Daily21d
Nwd1 gene deletion triggers MASH-like pathology in mice
Metabolic dysfunction-associated steatohepatitis (MASH ... A key factor in the pathology of MASH is the disruption of endoplasmic reticulum (ER) homeostasis. The ER stores calcium ions (Ca ...